↓ Skip to main content

Dove Medical Press

The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controll…

Overview of attention for article published in Neuropsychiatric Disease and Treatment, June 2021
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (52nd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter
3 X users

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
20 Mendeley
Title
The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials
Published in
Neuropsychiatric Disease and Treatment, June 2021
DOI 10.2147/ndt.s312011
Pubmed ID
Authors

Azmi Nasser, Joseph T Hull, Tesfaye Liranso, Gregory D Busse, Zare Melyan, Ann C Childress, Frank A Lopez, Jonathan Rubin

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 20 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 3 15%
Other 2 10%
Professor 2 10%
Student > Bachelor 1 5%
Professor > Associate Professor 1 5%
Other 0 0%
Unknown 11 55%
Readers by discipline Count As %
Psychology 2 10%
Chemistry 2 10%
Nursing and Health Professions 1 5%
Medicine and Dentistry 1 5%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Other 0 0%
Unknown 13 65%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 July 2021.
All research outputs
#14,925,951
of 25,392,582 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,360
of 3,131 outputs
Outputs of similar age
#215,552
of 459,810 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#24
of 60 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,131 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 459,810 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 60 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.